ArticleCancer immunology, immunotherapy : CII2025

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study.

Hongjie Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.